A recent study revealed that bevacizumab (Avastin) provides survival benefits in patients with colorectal cancer (CRC) for ...

and anti-VEGF drug Avastin (bevacizumab) already has a breakthrough designation from the FDA as a treatment for first-line HCC treatment. If approved, the Tecentriq/Avastin regimen would be the ...

Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric ...

3-year, 4-year and 5-year OS rate of patients who receive Atezo-Bev treatment, stratified by treatment response. 3 years 35.6 52.2 4 years 30.3 52.2 5 years 30.3 47.7 Responder: patients who achieved ...

The experimental therapy demonstrated a safety profile ... a six-month survival advantage with cancer drugs atezolizumab and bevacizumab, marketed as Tecentriq and Avastin by Roche (OTCQX:RHHBY ...